Solvonis Therapeutics plc announced the appointment of pharmaceutical industry veteran, Dr. Renata Crome DSc, MBA, MFPM, as an independent Non-Executive Director, effective from 11 March 2025. Dr. Crome brings over 40 years of experience in scientific and clinical development, regulatory approval, and commercialisation of breakthrough medicines. A recognised leader in CNS (Central Nervous System), oncology, and infectious diseases, Dr. Crome has guided more than 100 novel therapies from early-stage research to first-in-human clinical trials.
During her 30-year tenure at Roche, Dr. Crome progressed through increasingly senior roles, ultimately becoming Deputy Head of Early Development & Global Head of Development Operations. In this capacity, she led a team of over 250 professionals and managed a portfolio of more than 100 early development programmes across several therapeutic areas, including CNS, a key area of focus for Solvonis. Dr. Crome also served as a Non-Executive Director at Camcon Robotics and is a Trustee for the PTEN Research Foundation, Success Charity and Isabel Hospice.
Her involvement in academia includes lecturing at the University of Hertfordshire and chairing the Infectious Diseases Expert Group within the Faculty of Pharmaceutical Medicine's Policy & Communications Group.
